|
|
|
|
|
|
|
20.06.25 - 12:03
|
Clarus Debuts Its Redesigned Showroom at NeoCon 2025 (PR Newswire)
|
|
|
CHICAGO, June 20, 2025 /PRNewswire/ -- Clarus unveiled a fresh showroom layout and new glass concepts, including its first-ever digital glassboard at NeoCon 2025. The Clarus showroom has long been a NeoCon must-visit—known for its flashy spectacles, pulsing music, and sleek products, and......
|
|
|
|
|
06.06.25 - 00:03
|
ZEISS CLARUS 700 Receives NMPA Approval in China (PR Newswire)
|
|
|
ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 5, 2025 /PRNewswire/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical......
|
|
|
|
|
|
|
|
|
|
|
06.05.25 - 22:18
|
Clarus Announces $0.025 Per Share Quarterly Dividend (GlobeNewswire EN)
|
|
|
SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor enthusiast markets, announced that its board of directors has confirmed the Company's regular quarterly cash dividend of $0.025 per share....
|
|
|
24.04.25 - 22:18
|
Clarus Sets First Quarter 2025 Conference Call for Thursday, May 8, 2025, at 5:00 p.m. ET (GlobeNewswire EN)
|
|
|
SALT LAKE CITY, April 24, 2025 (GLOBE NEWSWIRE) -- Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor enthusiast markets, will hold a conference call on Thursday, May 8, 2025, at 5:00 pm ET to discuss its financial results for the first quarter ended March 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call....
|
|
|
09.04.25 - 13:03
|
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors (Business Wire)
|
|
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors.
Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment career, Dr. Cunningham has led or co-led financings that contributed to the FDA approval of ten therapeutics, including ophthalmic treatments such as Xiidra®, Rhopressa®, Rocklatan®, Syfovre®, and Izervay®.
He previously served as Senior Vice President of Medical Strategy at Eye...
|
|
|
27.03.25 - 18:02
|
Clarus Launches its First-Ever Digital Glassboard (PR Newswire)
|
|
|
FORT WORTH, Texas, March 27, 2025 /PRNewswire/ -- Glassboard leader Clarus introduces Lynk™, a wall-mounted touchscreen writing glassboard featuring 250+ apps, a multi-point touchscreen, and real-time remote collaboration abilities. Clarus says, "It is a teamwork tool that links......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
